PerkinElmer–Varex Imaging: investment, 201612–201705 acquisition $276m cash of PE’s medical imaging business by Varex Imaging (Varian Medical Systems) |
2016-12-22 |
C.B.S. Scientific–Genetrix (ES): investment, 201612 acquisition $900k of C.B.S. Scientific Company for $540k cash + $360k in shares by Sygnis AG |
2016-12-21 |
Purdue Pharma–Celltrion: rituximab, 201612– acquisition distribution rights for UK+IE+DE+IT+Benelux for biosimilar Truxima by Mundipharma |
2016-12-20 |
Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares |
2016-12-19 |
KKR–Lonza: investment, 201612–201707 acquisition of Capsugel for $5.5b in cash from KKR by Lonza |
2016-12-15 |
Noxxon–Merck (US): cancer immunotherapy, 201612– collab clinical research combi of Keytruda + NOX-A12 in metastatic colorectal + pancreatic cancer |
2016-12-15 |
Univercells–Gates Foundation: grant, 201612 grant $12m to reduce costs of vaccines for developing countries in collab w Batavia + Natrix |
2016-12-15 |
Carpegen–Lifescience Business Consulting: business consulting, 201612 supply portfolio/market analysis for sale of Gyronimo RT-PCR platform to Curetis |
2016-12-13 |
Carpegen–Osborne Clarke: legal services, 201612 supply legal advisor for sale of Carpegen’s Gyronimo RT-PCR platform to Curetis |
2016-12-13 |
Numares–Ruth Group: public relations, 201612 service existent US PR + IR by The Ruth Group |
2016-12-08 |
Acticor Biotech–Merck (DE): rec protein production, 201612– supply Provantage End-to-End Services for developm + manufacturing of Fab |
2016-12-05 |
Boehringer–Bruker: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System in Biberach |
2016-12-01 |
Medigene–Coulter Partners: recruitment services, 201612 supply service placement of Thomas Taapken as new CFO of Medigene |
2016-12-01 |
Phlexglobal–Vitruvian Partners: investment, 201612 investment by VIP II |
2016-12-01 |
Roche–Bruker: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System to Genentech |
2016-12-01 |
GeneWerk–GenoSafe: gene/cell therapy services, 201611– collab framwork agreem to offer combined research services |
2016-11-29 |
T3 Pharmaceuticals–OTHER: investment, 201611 1st financing round from private Swiss investors |
2016-11-23 |
OSE Immunotherapeutics–Selexis: cell line development, 201611– supply service access to research cell banks from SUREtechnology platform |
2016-11-15 |
Evotec–Univ Oxford: drug discovery, 201611– collab partnership LAB282 for early-stage projects out of Oxford Univ with OUI + OSI |
2016-11-10 |
Takeda–AstraZeneca: digital pathology, 201611– collab using Definiens' newly launched VeriTrova cloud-based solution |
2016-11-07 |
Aimmune Therapeutics–Nestlé: investment, 201611 equity investment $145m w 7.6m shares at $19.2/share by Nestlé Health Science |
2016-11-04 |
Nestlé–Aimmune Therapeutics: immunotherapy, 201611– strategic collab to develop + commercialise food allergy therapies w Neslé Health Science |
2016-11-04 |
Actelion–Reveragen: vamorolone, 201611– excl license option for Actelion |
2016-11-03 |
AMP-Therapeutics–EnBiotix: investment, 201611 acquisition of AMPT via asset acquisition by newly established EnBiotix GmbH |
2016-11-03 |
Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies |
2016-11-03 |
Leo Pharma–MorphoSys: therapeutic antibodies, 201611– collab strategic alliance to develop ABs in dermatology using Ylanthia technology |
2016-11-02 |
Q Laboratories–Bruker: mass spectrometer, 201611 supply MALDI Biotyper |
2016-11-01 |
Science 37–Novartis: investment, 201610 financing round Series B totalling $31m incl existing + co-investor dRx Capital |
2016-10-18 |
Science 37–SEVERAL: investment, 201610 financing round Series B $31m led by Redmile Group + incl Lux Capital + dRx Capital + SGBV |
2016-10-18 |
ObsEva–SEVERAL: investment, 201610–201701 IPO $96.75m+$14.513m w 645k+967.5k common shares at $15/share at Nasdaq Global Select Market |
2016-10-17 |
Max Planck–Labfolder: electronic lab notebook, 201610– supply license for up to 11k MPI researchers using Labfolder s/w |
2016-10-12 |
UgiSense–SEVERAL: investment, 201610 first financing round €1.2m from private investors |
2016-10-12 |
Selexis–Sam Brown: public relations, 201610 service existent by Sam Brown Inc |
2016-10-10 |
Noxxon–OTHER: investment, 201609 listing of ordinary shares on Alternext Paris [no new shares issued] |
2016-09-30 |
Noxxon–SEVERAL: investment, 201609 private placement just prior to listing of ordinary shares on Alternext Paris |
2016-09-30 |
Boehringer–Hospital Corp of America: clinical research, 201609– collab clinical developm of combi of 2 checkpoint inhibitors w Sarah Cannon Research |
2016-09-29 |
ICMP–Qiagen: MDx forensics, 201609– collab developm NGS workflow for identification of missing persons |
2016-09-29 |
Boehringer–ViraTherapeutics: cancer immunotherapy, 201609– long-term collab up to €210m to develop oncolytic virus platform + products |
2016-09-28 |
Noxxon–NewCap: public relations, 201609 service existent by NewCap |
2016-09-28 |
Evotec–France (govt): cancer drug discovery, 201609– research collab with Inserm in translational oncology |
2016-09-22 |
Polyplus-transfection–ArchiMed: investment, 201609 acquisition of majority stake by ArchiMed |
2016-09-19 |
PaxVax–Leukocare: drug formulation technology, 201609– license to SPS technology for one live viral vaccine product of PaxVax |
2016-09-13 |
Inflazome–Fountain Healthcare Partners: investment, 201609 financing round Series A totalling $17m incl founding investor FHP |
2016-09-12 |
Inflazome–Novartis: investment, 201609 financing round Series A totalling $17m incl founding investor Novartis Venture Fund |
2016-09-12 |
Inflazome–SEVERAL: investment, 201609 financing round Series A $17m from Novartis Venture Fund + Fountain Healthcare Partners |
2016-09-12 |
Curetis–Siemens: GEAR database, 201609 acquisition €na of ww rights to GEAR database + related IP + know-how by Curetis from STA |
2016-09-07 |
ViraTherapeutics–Boehringer: investment, 201809 acquisition of all remaining shares of ViraTby BI with total transaction value of €210m |
2016-08-01 |
Pro Farma–Recordati: investment, 201607 acquisition CHF16m 100% of Pro Farma AG by Recordati |
2016-07-14 |
Delenex–Cell Medica: investment, 201607 acquisition €na of Delenex Pharmaceuticals AG by Cell Medica |
2016-07-12 |
Charles River–Caprotec: CCMS technology, 201606 collab use of CCMS tech to identify protein targets relevant for phenotypic drug candidate responses |
2016-06-29 |
Storm Therapeutics–Merck (DE): investment, 201606 financing round Series A totalling £12m incl investor Merck Ventures |
2016-06-28 |
Storm Therapeutics–SEVERAL: investment, 201606 financing round Series A £12m with CIC + Merck Ventures + Pfizer Venture + Touchstone Innovations |
2016-06-28 |
Cosmo Pharmaceuticals–Paion: remimazolam, 201606– license excl €10m upfront + €42.5m milestones + royalties for developm + commercialisation in US |
2016-06-24 |
Grünenthal–AstraZeneca: lesinurad, 201606– license excl for Europe + Latin America to Zurampic + fixed dose combi of lesinurad + allopurinol |
2016-06-02 |
Celonis–SEVERAL: investment, 201606 financing round Series A $27.5m |
2016-06-01 |
Nouscom–Life Sciences Partners: investment, 201605 financing round Series A totalling €12m co-led by LSP + Versant Ventures |
2016-05-17 |
Nouscom–Versant Ventures: investment, 201605 financing round Series A totalling €12m co-led by LSP + Versant Ventures |
2016-05-17 |
LabCorp–Epigenomics: molecular diagnostics cancer test, 201605– distribution LabCorp to offer Epi proColon test in the US |
2016-05-09 |
G-Therapeutics–Gimv: investment, 201604 financing round Series A totalling €26m incl co-investor Gimv |
2016-04-19 |
Labiotech.eu–WestTech Ventures: investment, 201602 seed financing round totalling low €6-digit incl lead investor WestTech Ventures |
2016-02-03 |
Amgen–Biocartis: molecular companion diagnostics, 201712– collab €na developm liquid biopsy Idylla RAS CDx test for Vectibix |
2016-01-07 |
Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
Merus–Minapharm: GlymaxX technology, 2016– non-excl license agreem for use of GlymaxX for Biclonics pipeline from ProBioGen AG |
2016-01-01 |
MicrobeDx–Microfluidic ChipShop: microfluidics technology, 2016– collab developm + production of pharmacodiagnostic test systems |
2016-01-01 |
Probiodrug–Crossbeta Biosciences: biomarker research, 2016– collab developm Alzheimer biomarker to support Probiodrug’s clinical AD program |
2016-01-01 |
Storm Therapeutics–Evotec: drug discovery services, 2016– supply service HTS + structural biology to identify hits for 2 RNA modulating targets |
2016-01-01 |
Bridgepoint–KKR: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint |
2015-12-08 |
Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m |
2015-11-02 |
MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund |
2015-11-01 |
Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m |
2015-11-01 |
Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management |
2015-10-21 |
Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital |
2015-10-20 |
Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital |
2015-10-20 |
Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round |
2015-10-09 |
Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech |
2015-10-01 |
Baxalta–Novimmune: therapeutic antibodies, 201509– collab RnD €na bispecific antibodies for hemophilia A |
2015-09-02 |
Protembis–SEVERAL: investment, 201507 seed financing round 7-digit € incl Innovationsstarter Fonds + Geratherm + angel investors |
2015-07-28 |
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock |
2015-07-14 |
ViraTherapeutics–Austria (govt): investment, 201506 financing round Series A 1st closing totalling €3.6m incl co-investor aws |
2015-06-23 |
ViraTherapeutics–Boehringer: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures |
2015-06-23 |
ViraTherapeutics–EMBL: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures |
2015-06-23 |
Cyclenium–Haplogen: virostatic agents, 201505– collab drug discovery small molecule macroycle inhibitors using CMRT technology |
2015-05-01 |
Blueberry Therapeutics–SEVERAL: investment, 201504 financing round $1.75m from UK + Swiss investors |
2015-04-08 |
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital |
2015-03-04 |
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne |
2015-03-04 |
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund |
2015-03-04 |
Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures |
2015-03-04 |
Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One |
2015-03-04 |
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit |
2015-03-03 |
Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m |
2015-03-01 |
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m |
2015-02-01 |
Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion RnD small-molecule KRAS inhibitors for cancer |
2015-01-13 |
Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit € |
2015-01-01 |
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF |
2015-01-01 |
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain |
2015-01-01 |
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors |
2015-01-01 |
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures |
2015-01-01 |
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp |
2015-01-01 |